title: The economics of cardiovascular disease in the United States.
abstract: Cardiovascular disease is the leading cause of death in the United States,and thus its clinical and economic implications are enormous. In an increasingly cost-conscious economic environment, it is important to understand not only the effectiveness of treatments and technologies but also their cost-effectiveness. The authors review and summarize the evidence on cost-effectiveness of surgical versus medical treatments. This evidence should prove useful at the patient bedside as well as assist policymakers and third party payers in deciding what treatments to cover.
authors: Department of Political Science, Economics, and Philosophy, City University of New York, College of Staten Island, 2800 Victory Boulevard, Room 2N-226, Staten Island, NY 10314, USA.
authors: Jie
authors: J
authors: Chen
authors: John A
authors: JA
authors: Rizzo
mesh_terms: D002318:Cardiovascular Diseases / Q000191:economics* / Q000453:epidemiology / Q000628:therapy; D013504:Cardiovascular Surgical Procedures / Q000191:economics*; D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D014481:United States / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors